NSE PPLPHARMA · BSE 543635 · Biotechnology & Drugs · NIFTY 500

Piramal Pharma Share Price

Market open · NSE price as of Mon 28 Sep
₹206.59 ▼ −₹3.72 · 1.77%
Day range · 28 Sep
₹205.25Low₹212.30High
52-week range
₹132.50Low · 23 Mar 2026₹231.85High · 8 Sep 2026

Piramal Pharma Overview

Where the price stands, how it has moved and how it sits against its averages.

Piramal Pharma shares last traded at ₹206.59 on the NSE, down 1.77% on the day. That is 10.9% below the 52-week high of ₹231.85 and 55.9% above the 52-week low of ₹132.50. Its market value is ₹27,504 Cr.

NSE closing prices — daily for the last year, weekly before that — ending at the latest price (Mon 28 Sep). Hover, tap or use the arrow keys to read a day.

Price returns

1 Day▼ −1.77%
1 Week▼ −3.76%
This month▼ −3.64%
3 Months▲ +23.20%
6 Months▲ +43.90%
This year▲ +19.96%
1 Year▲ +10.05%

Share price growth a year (CAGR): 3 years ▲ +28.2%

Against the market: 1 Month ▲ +0.56% · 3 Months ▲ +30.86% · 6 Months ▲ +45.88% · This year ▲ +40.84% · 1 Year ▲ +18.33%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST). Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 3 of 6

  1. 20-day average₹212.48 ▼ price 2.8% below
  2. 5-day average₹210.79 ▼ price 2.0% below
  3. 10-day average₹208.40 ▼ price 0.9% below
  4. Today's price₹206.59
  5. 50-day average₹205.79 ▲ price 0.4% above
  6. 100-day average₹188.43 ▲ price 9.6% above
  7. 300-day average₹174.28 ▲ price 18.5% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Piramal Pharma Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
9,151
8,869
Net profit₹ crore · losses below zero
572
−326

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹8,869 Cr ▼ −3.1% −₹326 Cr −3.7% −₹2.46 ₹0.00
FY 2025 ₹9,151 Cr ▲ +12.0% ₹91 Cr 1.0% ₹0.68 ₹0.14
FY 2024 ₹8,171 Cr ▲ +15.4% ₹18 Cr 0.2% ₹0.14 ₹0.11
FY 2023 ₹7,082 Cr ▲ +8.0% −₹186 Cr −2.6% −₹1.53 —
FY 2022 ₹6,559 Cr ▲ +123.2% ₹376 Cr 5.7% ₹3.11 ₹0.00
FY 2021 ₹2,939 Cr — ₹572 Cr 19.4% ₹4.71 ₹0.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
55%
45%
  • Total assets₹17,965 Cr
  • Total liabilities₹9,802 Cr
  • Shareholders' equity₹8,163 Cr
  • Total debt₹5,675 Cr
  • Cash & investments₹1,332 Cr
  • Current ratio1.51×
  • Revenue growth, 5 yr24.72% a year
  • Operating margin (TTM)−0.70%
  • Net margin (TTM)−3.41%

Cash flow — FY26

Operating activities
▲ ₹1,653 Cr
Investing activities
▼ −₹826 Cr
Financing activities
▼ −₹39 Cr
Free cash flow
▲ ₹763 Cr
Net change in cash
▲ ₹794 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY21–FY26
₹ croreFY21FY22FY23FY24FY25FY26
Total revenue2,938.816,559.107,081.558,171.169,151.188,869.08
Cost of revenue1,227.762,614.802,911.113,195.593,498.813,498.72
Gross profit1,711.053,944.304,170.444,975.575,652.375,370.36
Operating expenses1,844.835,264.905,937.626,683.378,442.528,868.83
Operating income1,093.981,294.201,143.931,487.79708.660.25
Depreciation143.64586.18676.69740.57771.59824.26
Profit before tax686.78484.98−120.15179.29414.64−176.06
Tax115.28109.0266.31161.47323.51149.88
Net profit571.50375.96−186.4617.8291.13−325.94
EPS (₹)4.713.11−1.530.140.68−2.46
Dividend per share (₹)0.000.00—0.110.140.00

Piramal Pharma vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Piramal Pharma This stock ₹206.59 ▼ −1.77% ₹27,504 Cr −87.70 3.36 −0.08% −3.41% 0.00%
Sun Pharmaceutical Industries ₹1,840.00 ▼ −0.73% ₹4,41,467 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,531.50 ▼ −0.82% ₹2,53,031 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,869.40 ▼ −2.32% ₹1,85,210 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,388.90 ▼ −0.59% ₹1,12,203 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,212.00 ▲ +0.83% ₹1,20,897 Cr 21.19 4.24 17.90% 18.51% 0.09%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Piramal Pharma shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
34.8%
12.5%
13.2%
39.5%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter34.86%34.86%34.86%34.80% ▼ −0.06 pts
FII30.27%29.66%30.17%12.51% ▼ −17.66 pts
MF13.11%14.03%14.12%13.18% ▼ −0.94 pts
Other21.76%21.45%20.85%39.51% ▲ +18.66 pts

Piramal Pharma Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Piramal PharmaBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
−87.70
Loss-making over 12 months — P/E not meaningful
P/BPrice ÷ book value per share
3.36
P/SMarket cap ÷ last 12 months' revenue
2.99
P/CFPrice ÷ cash flow per share
51.24

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
63.10%
▲ above its 5-yr average of 60.54%
Operating marginKept after running costs
−0.70%
▼ below its 5-yr average of 11.64%
Pre-tax marginKept before tax
−1.14%
▼ below its 5-yr average of 1.97%
Net marginKept as profit
−3.41%
▼ below its 5-yr average of −0.07%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
−4.00%
▼ below its 5-yr average of −0.08%
Return on assetsProfit on everything it owns
−1.94%
▼ below its 5-yr average of −0.04%
Return on investmentProfit on long-term capital
−2.60%
▼ below its 5-yr average of −0.05%
Return on capital employedProfit before interest and tax on equity + debt
0.20%

Growth Is the business getting bigger?

Revenue — last 12 months
+0.8%
▲ growing
Revenue — 3 yr, a year
+7.8%
▲ growing
Revenue — 5 yr, a year
+24.7%
▲ growing
EPS — last 12 months
−426.9%
▼ shrinking (off the scale)
Book value — 5 yr, a year
+12.7%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.70×
• Moderate
Current ratioShort-term assets for every ₹1 due within a year
1.51×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
0.83×
• Adequate
Interest coverOperating profit ÷ interest to pay
1.26×
! Weak

Per share What each share stands for

EPS (TTM)
−₹2.37
Book value
₹61.50
Cash flow
₹4.10
Dividend
₹0.00
Revenue
₹69.47

The share price is 3.36× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 92 metrics from the data provider

Valuation

Current Dividend Yield - Common Stock Primary Issue, LTM0.00
Price to Book - most recent fiscal year3.42
Price to Tangible Book - most fiscal year6.93
Price to sales - most recent fiscal year3.14
Price to Cash Flow per share - trailing 12 month51.24
Price to Free Cash Flow per Share - most recent fiscal year37.45
Price to sales - trailing 12 month3.03
Net Debt, LFY43,429.30

Per share

Cash Flow per share - trailing 12 month4.10
Cash Flow per share - most recent fiscal year3.76
EPS including extraordinary items - trailing 12 month−2.37
EPS including extraordinary items - most recent fiscal year−2.46
EBITD per share - trailing 12 month7.62
Revenue/share - trailing 12 month69.47
EPS excluding extraordinary items - trailing 12 month−2.37
EPS Basic excluding extraordinary items - most recent fiscal year−2.46
EPS Basic excluding extraordinary items - trailing 12 month−2.37
Book value per share - most recent fiscal year61.50
Dividend per share - most recent fiscal year0.00
Revenue/share - most recent fiscal year66.92
EPS Normalized - most recent fiscal year−1.22
Book value (tangible) per share - most recent fiscal year30.30
Dividends per share - trailing 12 month0.00
EPS excluding extraordinary items - most recent fiscal year−2.46
Cash per share - most recent fiscal year10.03

Margins

Operating margin - trailing 12 month−0.70
Gross Margin - 5 year average60.54
Operating margin - 1st historical fiscal year0.00
Operating Margin - 5 year average11.64
Net Profit Margin % - 1st historical fiscal year−3.68
Gross Margin - 1st historical fiscal year60.55
Net Profit Margin % - trailing 12 month−3.41
Net Profit Margin - 5 year average−0.07
Pretax Margin - 5 year average1.97
Pretax margin - 1st historical fiscal year−1.99
Pretax margin - trailing 12 month−1.14
Free Operating Cash Flow/Revenue, 5 Year Average1.52
Gross Margin - trailing 12 month63.10

Growth

EPS Change %, TTM over TTM−426.87
Revenue growth rate, 5 year24.72
Revenue Change % - most recent quarter 1 year ago17.39
Revenue/share (5 yr growth)22.56
Tangible Book Value, Total Equity, 5 Year CAGR1.47
Capital Spending growth rate, 5 year72.60
Revenue Change %, TTM over TTM0.78
Growth rate% - Revenue, 3 year7.79
Book value per share growth rate, 5 year12.74
EPS Change % - most recent quarter 1 year ago16.13
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR−2.68
Total Debt, 5 Year CAGR100.70

Financial strength

Net Interest coverage - most recent fiscal year1.26
Free Cash Flow - most recent fiscal year7,440.20
LT debt/equity - most recent fiscal year0.54
Quick ratio - most recent fiscal year0.83
Current ratio - most recent fiscal year1.51
Total debt/total equity - most recent fiscal year0.70
Net Interest coverage - trailing 12 month0.54

Returns & efficiency

Return on average equity - 5 year average−0.08
Net Income/employee - trailing 12 month−4,40,491.60
Revenue/employee - most recent fiscal year1,24,51,330.00
Return on investment - most recent fiscal year−2.60
Return on average assets - most recent fiscal year−1.94
Receivables turnover - most recent fiscal year3.87
Inventory turnover - most recent fiscal year1.23
Revenue/employee - trailing 12 month1,29,28,760.00
Return on average assets - 5 year average−0.04
Net Income/employee - most recent fiscal year−4,57,588.10
Asset turnover - most recent fiscal year0.53
Return on average equity - most recent fiscal year−4.00
Return on investment - 5 year average−0.05

Price & volume

Market Cap27,485.68
52 week Low Date23 Mar 2026
Price - 1 Day % Change1.05
Relative (S&P500) price percent change - 13 week30.86
Avg trading volume last 10 days3.23
Price - 13 week price percent change25.42
Price - 52 week price percent change7.74
Avg Trading Volume Last 3 months128.76
Price - 5 Day % Change1.03
Price % Change Month To Date−1.91
Relative (S&P500) price percent change - 04 week0.56
52 week High Date8 Sep 2026
Price - 26 week price percent change46.50
PDATE25 Sep 2026
Price - YTD price percent change22.12
Relative (S&P500) price percent change - 52 week18.33
NPRICE210.31
Relative (S&P500) price percent change - 26 week45.88
52 week Low132.30
52 week High231.93
Beta1.38
Relative (S&P500) price percent change - Year to Date40.84

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹0.14
₹0.00
  • Dividend yield0.00%
  • Latest dividend₹0.11 per share · 12 Jul 2024

Corporate calendar

  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • BoardAudited Results
  • BoardQuarterly Results
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
  • BoardAudited Results & Final Dividend
Show 8 older events
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹0.11 per share · 1% · Final dividend
  • RightsRights issue of equity shares of ₹ 10/- in the ratio of 5:46 @ premium of ₹ 71/-.
  • MeetingAnnual General Meeting
  • MeetingPostal Ballot

About Piramal Pharma

Biotechnology & Drugs

Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.

Key people

  • Nandini A. PiramalExecutive Chairman of the Board
  • Vivek ValsarajChief Financial Officer, Executive Director
  • Maneesh SharmaCompliance Officer, Company Secretary
  • Peter DeYoungExecutive Director, Chief Executive Officer of Global Pharma

Company facts

  • NSE symbolPPLPHARMA
  • BSE code543635
  • ISININE0DK501011
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹27,504 Cr
  • Revenue (FY26)₹8,869 Cr
  • Net profit (FY26)−₹326 Cr

In the News

Recent headlines about Piramal Pharma — they open on Mint in a new tab.

  • Mint Sustainability Impact Summit 2026: the new economics of responsibility

    The Mint Sustainability Impact Summit 2026 will address the evolving landscape of sustainability amid geopolitical tensions and AI's rise. It will explore how businesses can balance decarbonization, competitiveness and resilience while facing escalating climate risks and energy security concerns.

    29 Jul 2026 · 4 min read · Mint ↗

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Piramal Pharma (NSE: PPLPHARMA) last traded at ₹206.59 on the NSE, down 1.77% (₹3.72) on the day, as of 28 Sep 2026. The day's range was ₹205.25 – ₹212.30.

Piramal Pharma's 52-week high is ₹231.85 (8 Sep 2026) and its 52-week low is ₹132.50 (23 Mar 2026). At ₹206.59 the share is 10.9% below its high and 55.9% above its low.

Piramal Pharma's market capitalisation is ₹27,504 Cr (₹27,504 Cr). It is part of the NIFTY 500 index.

Piramal Pharma made a loss over the last 12 months, so its P/E ratio is not meaningful. Its earnings per share (TTM) are −₹2.37.

Piramal Pharma shares are up 10.05% over the last year, up 19.96% so far this year, up 43.90% over 6 months, up 23.20% over 3 months. Over the last year the stock did 18.33% better than the market.

In FY26 (year to Mar 2026), Piramal Pharma reported revenue of ₹8,869 Cr (down 3.08% on the year before) and a net loss of ₹326 Cr. Earnings per share were −₹2.46.

Yes. Piramal Pharma's latest dividend is ₹0.11 per share (1%, final dividend), with an ex-date of 12 Jul 2024. The dividend yield is 0.00%. It has paid 2 dividends in the records shown on this page.

As of Jun 2026: Promoter 34.80%, FII 12.51%, MF 13.18%, Other 39.51%. Promoter holding fell by 0.06 percentage points from Mar 2026.

Piramal Pharma's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

No. Piramal Pharma has debt — its debt-to-equity ratio is 0.70 and total debt was ₹5,675 Cr in FY26. Its operating profit covers interest 1.26 times.